MIA PaCa-2-hCLDN18.2
品系基本信息
*使用本品系發(fā)表的文獻需注明: MIA PaCa-2-hCLDN18.2 cell line (Cat. NO. NMC-230095) was purchased from Shanghai Model Organisms Center, Inc..
驗證數(shù)據(jù)
Ⅰ.In vitro?Expression of MIA Paca-2-hCLDN18.2 cell line
Figure?1. hCLDN18.2 expression in MIA Paca-2 and MIA Paca-2-hCLDN18.2 cell lines
Ⅱ.Characterization of in vivo?growth kinetics
To test the take rates, and?the tumor growth characteristics of MIA Paca-2 -hCLDN18.2 cell line, cells?were subcutaneously inoculated into the M-NSG mice.
Figure?2. Tumor growth curve of MIA Paca-2-hCLDN18.2 xenograft model?model (n=5)
Figure?3. Body weight change of MIA Paca-2-hCLDN18.2 xenograft model?model (n=5)
Ⅲ.Expression of hCLDN18.2 protein in tumors
To verify the hCLDN18.2 protein expression, the tumors were dissected and separated for single cell suspension.
Figure?4. The expression of hCLDN18.2 in humanized modified tumors by FACS
你也可能感興趣
Tamoxifen誘導Cre-ERT2小鼠 使用指南
Cre-ERT2在無Tamoxifen誘導的情況下，在細胞質(zhì)內(nèi)處于無活性狀態(tài)；當Tamoxifen誘導后，Tamoxifen的代謝產(chǎn)物4-OHT（雌激素類似物）與ERT結(jié)合，可使Cre-ERT2進核發(fā)揮Cre重組酶活性。
查看
